- Original article
- Open Access
Magnetic resonance spectroscopy in evaluating cerebral metabolite imbalance in chronic obstructive pulmonary disease
Egyptian Journal of Bronchology volume 12, pages 14–19 (2018)
Magnetic resonance spectroscopy (MRS) is a powerful research tool and has been proved to provide additional clinically relevant information for several diseases such as brain tumors, metabolic disorders, and systemic diseases.
The aims of this study were to evaluate cerebral metabolic imbalance in chronic obstructive pulmonary disease (COPD) and to correlate the abnormalities with spirometric and gasometric parameters.
Patients and methods
In a case–control study, eight COPD patients and eight age-matched and sex-matched healthy control individuals were compared. 1H-MRS was performed using 1.5-T MRI/MRS scanner. Using 1H-MRS single-voxel technique, N-acetyl aspartate/choline (NAA/Cho), choline/ creatine (Cho/Cr), and N-acetyl aspartate/creatine (NAA/Cr) ratios were estimated and compared in both groups.
There were significant differences regarding the distribution of neurotransmitters in the temporal lobe only between COPD and control groups; there were significant positive correlations between the NAA/Cho ratio at the thalamus with both partial pressure of arterial carbon dioxide and base excess or base deficit. However, there was a significant positive correlation between the Cho/Cr ratio at the thalamus and forced vital capacity (l), and a significant positive correlation between the NAA/Cr ratio at the thalamus andBMI, and a negative correlation between the NAA/Cr ratio at the thalamus and partial pressure of arterial oxygen. There was a significant negative correlation between theNAA/Cr ratio at the temporal lobe and partial pressure of arterial carbon dioxide.
MRS provided an insight to study the neurochemical changes that occur in COPD patients. Chronic hypoxemia and hypercapnia seem to play a key role in the pathophysiology of neurochemical changes in COPD.
Ryner LN, Sorenson JA, Thomas MA. Localized 2D J-resolved 1H MR spectroscopy: strong coupling effects in vitro and in vivo. Magn Reson Imaging 1995; 13:1043–1048.
Bottomley PA. Spatial localization in NMR spectroscopy in vivo. Ann N Y Acad Sci. 1987; 508:333–348.
Provencher SW. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med 1993; 30:672–679.
Borson S, Scanlan J, Friedman S, Zuhr E, Fields J, Aylward E, et al. Modeling the impact of COPD on the brain. Int J Chron Obstruct Pulmon Dis 2008; 3:429–434.
Antonelli-Incalzi R, Chiappini F, Fuso L, Torrice MP, Gemma A, Pistelli R. Predicting cognitive decline in patients with hypoxaemic COPD. Respir Med 1998; 92:527–533.
Friedman SD, Brooks WM, Jung RE. Quantitative proton MRS predicts outcome after traumatic brain injury, Neurology 1999; 52:1384–1391.
Forton DM, Allsop JM, Cox IJ. A review of cognitive impairment and cerebral metabolite abnormalities in patients with hepatitis C infection. AIDS 2005; 3:53–63.
Ross B, Michaelis T. Clinical applications of magnetic resonance. Magn Reson 1994; 10:191–247.
Mathur R, Cox IJ, Oatridge A, Shephard DT, Shaw RJ, Taylor-Robinson SD. Cerebral bioenergetics in stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 160:1994–1999.
Shim TS, Lee JH, Kim SY. Cerebral metabolic abnormalities in COPD patients detected by localized proton magnetic resonance spectroscopy. Chest 2001; 120:1506–1513.
Karakas E, Yildizhan M, Karakas O, Boyaci FN, Cullu N, Cece H, et al. Examining cerebral metabolic abnormalities in chronic obstructive pulmonary disease (COPD) patients by localized proton magnetic resonance spectroscopy (MRS). Clin Ter 2013; 164:179–182.
Sinha S, Virendra K, Jagannathan NR, Ravindra MP. Proton magnetic resonance spectroscopy of brain to study the cerebral metabolic abnormalities in COPD patients: a case control study in North India. Indian J Chest Dis Allied Sci 2009; 51:15–19.
El-Helbawy R, Yasin R, Shawky M. Value of proton magnetic resonance spectroscopy of brain to study the cerebral metabolic abnormalities in COPD: initial experience. Egypt J Chest Dis Tuberc 2014; 63:73–80.
Gallinat J, Meisenzahl E, Jacobsen LK, Kalus P, Bierbrauer J, Kienast T. Smoking and structural brain deficits: a volumetric MR investigation. Eur J Neurosci 2006; 24:1744–1750.
Gallinat J, Lang UE, Jacobsen LK, Bajbouj M, Kalus P, von Haebler D. Abnormal hippocampal neurochemistry in smokers: evidence from proton magnetic resonance spectroscopy at 3T. J Clin Psychopharmacol 2007; 27:80–84.
Michaelis T, Boretius S, Frahm J. Localized proton MRS of animal brain in vivo: models of human disorders. Prog Nucl Magn Reson Spectrosc 2009; 55:1–34.
Takashi W, Frahm J, Michaelis T. Amide proton signals as pH indicator for in vivo MRS and MRI of the brain – responses to hypercapnia and hypothermia. Neuroimage 2016; 133:390–398.
Tonon C, Roberto V, Raffaele L, Roberto G, Federica P, Stefano L, et al. Proton magnetic resonance spectroscopy study of brain metabolism in obstructive sleep apnea syndrome before and after continuous positive airway pressure treatment. Sleep 2007; 30:23–28.
This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work noncommercially, as long as the author is credited and the new creations are licensed under the identical terms.
About this article
Cite this article
El-Shinnawy, O.M., Khedr, E.M., Metwally, M.M. et al. Magnetic resonance spectroscopy in evaluating cerebral metabolite imbalance in chronic obstructive pulmonary disease. Egypt J Bronchol 12, 14–19 (2018). https://doi.org/10.4103/ejb.ejb_28_17
- cerebral bioenergetics in chronic obstructive pulmonary disease
- cerebral metabolite imbalance in chronic obstructive pulmonary disease
- magnetic resonance spectroscopy in chronic obstructive pulmonary disease